BidaskClub upgraded shares of Ascendis Pharma A/S (NASDAQ:ASND) from a buy rating to a strong-buy rating in a report issued on Thursday, BidAskClub reports.

ASND has been the topic of several other reports. Wedbush set a $217.00 price objective on Ascendis Pharma A/S and gave the company an outperform rating in a research note on Thursday, March 7th. Evercore ISI initiated coverage on Ascendis Pharma A/S in a research note on Monday, March 25th. They issued an outperform rating on the stock. Credit Suisse Group reduced their price objective on Ascendis Pharma A/S from $151.00 to $139.00 and set an outperform rating on the stock in a research note on Friday, March 29th. Cantor Fitzgerald reaffirmed an overweight rating and issued a $185.00 price objective (up from $102.00) on shares of Ascendis Pharma A/S in a research note on Monday, March 4th. Finally, JPMorgan Chase & Co. lifted their price objective on Ascendis Pharma A/S from $85.00 to $145.00 and gave the company an overweight rating in a research note on Thursday, March 7th. One equities research analyst has rated the stock with a hold rating, nine have issued a buy rating and two have given a strong buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $136.78.

ASND opened at $124.66 on Thursday. The stock has a market capitalization of $5.41 billion, a price-to-earnings ratio of -33.33 and a beta of 0.94. Ascendis Pharma A/S has a 12 month low of $53.21 and a 12 month high of $131.76.

Ascendis Pharma A/S (NASDAQ:ASND) last released its quarterly earnings data on Wednesday, April 3rd. The biotechnology company reported ($0.87) earnings per share for the quarter, beating the consensus estimate of ($1.17) by $0.30. The business had revenue of $12.00 million for the quarter. Ascendis Pharma A/S had a negative return on equity of 45.55% and a negative net margin of 901.89%. As a group, equities research analysts forecast that Ascendis Pharma A/S will post -3.93 earnings per share for the current fiscal year.

Institutional investors have recently added to or reduced their stakes in the stock. venBio Select Advisor LLC lifted its position in Ascendis Pharma A/S by 0.8% during the 4th quarter. venBio Select Advisor LLC now owns 1,980,000 shares of the biotechnology company’s stock worth $124,047,000 after acquiring an additional 16,664 shares in the last quarter. Squarepoint Ops LLC acquired a new position in Ascendis Pharma A/S during the 4th quarter worth approximately $204,000. Virtus ETF Advisers LLC acquired a new position in Ascendis Pharma A/S during the 4th quarter worth approximately $300,000. Morgan Stanley lifted its position in Ascendis Pharma A/S by 53.6% during the 3rd quarter. Morgan Stanley now owns 47,100 shares of the biotechnology company’s stock worth $3,338,000 after acquiring an additional 16,434 shares in the last quarter. Finally, FMR LLC lifted its position in Ascendis Pharma A/S by 1.2% during the 4th quarter. FMR LLC now owns 4,203,246 shares of the biotechnology company’s stock worth $263,333,000 after acquiring an additional 50,984 shares in the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia.

See Also: Sell-Side Analysts

Analyst Recommendations for Ascendis Pharma A/S (NASDAQ:ASND)

Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.